FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170554697> ?p ?o ?g. }

• W2170554697 endingPage "874" @default.
• W2170554697 startingPage "870" @default.
• W2170554697 abstract "Background The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects. Materials and methods We conducted a prospective surveillance study on patients diagnosed with pulmonary hypertension at 12 large referral centers in North America. Data collected on patients seen from September 1, 1996, to December 31, 1997, included the cause of the pulmonary hypertension and its severity. Patients with no identifiable cause of pulmonary hypertension were classed as PPH. A history of drug exposure also was taken with special attention on the use of antidepressants, anorexigens, and amphetamines. Results Five hundred seventy-nine patients were studied, 205 with PPH and 374 with pulmonary hypertension from other causes (secondary pulmonary hypertension [SPH]). The use of anorexigens was common in both groups. However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use> 6 months, 7.5; 95% confidence interval, 1.7 to 32.4). The association was stronger with longer duration of use when compared to shorter duration of use and was more pronounced in recent users than in remote users. An unexpectedly high (11.4%) number of patients with SPH had used anorexigens. Conclusion The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH. The high prevalence of anorexigen use in patients with SPH also raises the possibility that these drugs precipitate pulmonary hypertension in patients with underlying conditions associated with SPH. The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects. We conducted a prospective surveillance study on patients diagnosed with pulmonary hypertension at 12 large referral centers in North America. Data collected on patients seen from September 1, 1996, to December 31, 1997, included the cause of the pulmonary hypertension and its severity. Patients with no identifiable cause of pulmonary hypertension were classed as PPH. A history of drug exposure also was taken with special attention on the use of antidepressants, anorexigens, and amphetamines. Five hundred seventy-nine patients were studied, 205 with PPH and 374 with pulmonary hypertension from other causes (secondary pulmonary hypertension [SPH]). The use of anorexigens was common in both groups. However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use> 6 months, 7.5; 95% confidence interval, 1.7 to 32.4). The association was stronger with longer duration of use when compared to shorter duration of use and was more pronounced in recent users than in remote users. An unexpectedly high (11.4%) number of patients with SPH had used anorexigens. The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH. The high prevalence of anorexigen use in patients with SPH also raises the possibility that these drugs precipitate pulmonary hypertension in patients with underlying conditions associated with SPH." @default.
• W2170554697 created "2016-06-24" @default.
• W2170554697 creator A5004416630 @default.
• W2170554697 creator A5006434846 @default.
• W2170554697 creator A5011075689 @default.
• W2170554697 creator A5021742773 @default.
• W2170554697 creator A5042449331 @default.
• W2170554697 date "2000-03-01" @default.
• W2170554697 modified "2023-10-16" @default.
• W2170554697 title "Anorexigens and Pulmonary Hypertension in the United States" @default.
• W2170554697 cites W2009991668 @default.
• W2170554697 cites W2014466515 @default.
• W2170554697 cites W2030962869 @default.
• W2170554697 cites W2093102581 @default.
• W2170554697 cites W2134367539 @default.
• W2170554697 cites W2140148084 @default.
• W2170554697 cites W2327192631 @default.
• W2170554697 cites W2329065056 @default.
• W2170554697 cites W3144384179 @default.
• W2170554697 doi "https://doi.org/10.1378/chest.117.3.870" @default.
• W2170554697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10713017" @default.
• W2170554697 hasPublicationYear "2000" @default.
• W2170554697 type Work @default.
• W2170554697 sameAs 2170554697 @default.
• W2170554697 citedByCount "181" @default.
• W2170554697 countsByYear W21705546972012 @default.
• W2170554697 countsByYear W21705546972013 @default.
• W2170554697 countsByYear W21705546972014 @default.
• W2170554697 countsByYear W21705546972015 @default.
• W2170554697 countsByYear W21705546972016 @default.
• W2170554697 countsByYear W21705546972017 @default.
• W2170554697 countsByYear W21705546972018 @default.
• W2170554697 countsByYear W21705546972019 @default.
• W2170554697 countsByYear W21705546972020 @default.
• W2170554697 countsByYear W21705546972021 @default.
• W2170554697 countsByYear W21705546972022 @default.
• W2170554697 countsByYear W21705546972023 @default.
• W2170554697 crossrefType "journal-article" @default.
• W2170554697 hasAuthorship W2170554697A5004416630 @default.
• W2170554697 hasAuthorship W2170554697A5006434846 @default.
• W2170554697 hasAuthorship W2170554697A5011075689 @default.
• W2170554697 hasAuthorship W2170554697A5021742773 @default.
• W2170554697 hasAuthorship W2170554697A5042449331 @default.
• W2170554697 hasConcept C126322002 @default.
• W2170554697 hasConcept C156957248 @default.
• W2170554697 hasConcept C170493617 @default.
• W2170554697 hasConcept C187212893 @default.
• W2170554697 hasConcept C197934379 @default.
• W2170554697 hasConcept C2775864247 @default.
• W2170554697 hasConcept C2776135927 @default.
• W2170554697 hasConcept C2779638493 @default.
• W2170554697 hasConcept C2780930700 @default.
• W2170554697 hasConcept C44249647 @default.
• W2170554697 hasConcept C512399662 @default.
• W2170554697 hasConcept C71924100 @default.
• W2170554697 hasConceptScore W2170554697C126322002 @default.
• W2170554697 hasConceptScore W2170554697C156957248 @default.
• W2170554697 hasConceptScore W2170554697C170493617 @default.
• W2170554697 hasConceptScore W2170554697C187212893 @default.
• W2170554697 hasConceptScore W2170554697C197934379 @default.
• W2170554697 hasConceptScore W2170554697C2775864247 @default.
• W2170554697 hasConceptScore W2170554697C2776135927 @default.
• W2170554697 hasConceptScore W2170554697C2779638493 @default.
• W2170554697 hasConceptScore W2170554697C2780930700 @default.
• W2170554697 hasConceptScore W2170554697C44249647 @default.
• W2170554697 hasConceptScore W2170554697C512399662 @default.
• W2170554697 hasConceptScore W2170554697C71924100 @default.
• W2170554697 hasIssue "3" @default.
• W2170554697 hasLocation W21705546971 @default.
• W2170554697 hasLocation W21705546972 @default.
• W2170554697 hasOpenAccess W2170554697 @default.
• W2170554697 hasPrimaryLocation W21705546971 @default.
• W2170554697 hasRelatedWork W1774906049 @default.
• W2170554697 hasRelatedWork W2009038775 @default.
• W2170554697 hasRelatedWork W2012358447 @default.
• W2170554697 hasRelatedWork W2053221007 @default.
• W2170554697 hasRelatedWork W2147550791 @default.
• W2170554697 hasRelatedWork W2155233692 @default.
• W2170554697 hasRelatedWork W2531184019 @default.
• W2170554697 hasRelatedWork W2580849823 @default.
• W2170554697 hasRelatedWork W2754776629 @default.
• W2170554697 hasRelatedWork W3206370520 @default.
• W2170554697 hasVolume "117" @default.
• W2170554697 isParatext "false" @default.
• W2170554697 isRetracted "false" @default.
• W2170554697 magId "2170554697" @default.
• W2170554697 workType "article" @default.